Figure 4

Overlap and performance analysis of 724 samples with distant metastasis-free survival as the endpoint. (a) Distribution of the samples as a function of the number of times a sample was classified as of poor prognosis by the gene signatures. (b) Distribution of metastasis events as a function of the number of times a sample was classified as of poor prognosis by the gene expression signatures. (c) Distribution of estrogen receptor (ER)-negative samples as a function of the number of times a sample was classified as of poor prognosis by the gene signatures. (d) Distribution of HER2 amplified samples as a function of the number of times a sample was classified as of poor prognosis by the gene signatures. (e) Tumor size (mean, 5th, 25th, 75th and 95th percentiles) as a function of the number of times a sample was classified as of poor prognosis by the gene signatures. (f) Distribution of grade I, grade II and grade III samples (Elston Ellis) as a function of the number of times a sample was classified as of poor prognosis by the gene signatures. Dark shading, grade I; grey shading, grade II; pale shading, grade III. (g) Average predictive accuracy (percentage of samples well classified) as a function of the number of times a sample was classified as of poor prognosis by the gene signatures.